Home › Research › Biomarkers
Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity
Honig LS, Kang MS, Lee AJ, Reyes-Dumeyer D, Piriz A, Soriano B, Franco Y, Coronado ZD et al.. JAMA network open, 2023-04-03
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
These results suggest that plasma biomarkers can augment detection of preclinical AD among asymptomatic individuals and improve the specificity of AD diagnosis.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 746 participants. This cross-sectional study evaluated plasma biomarkers for classifying Alzheimer's disease among adults of Caribbean Hispanic ethnicity. Reported effect size: 64.3%; 20.6%; 22.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Honig, L. S., Kang, M. S., Lee, A. J., Reyes-Dumeyer, D., Piriz, A., Soriano, B., et al. (2023). Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2023.8214
Vancouver
Honig LS, Kang MS, Lee AJ, Reyes-Dumeyer D, Piriz A, Soriano B, et al. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity. JAMA network open. 2023. doi:10.1001/jamanetworkopen.2023.8214. PMID: 37079306.
BibTeX
@article{honig2023-37079306,
author = {Honig, L. S. and Kang, M. S. and Lee, A. J. and Reyes-Dumeyer, D. and Piriz, A. and Soriano, B. and Franco, Y. and Coronado, Z. D. and others},
title = {{Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity}},
journal = {JAMA network open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.8214},
pmid = {37079306},
url = {https://doi.org/10.1001/jamanetworkopen.2023.8214}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- These results suggest that plasma biomarkers can augment detection of preclinical AD among asymptomatic individuals and improve the specificity of AD diagnosis.
Why it matters
This cross-sectional study evaluated plasma biomarkers for classifying Alzheimer's disease among adults of Caribbean Hispanic ethnicity. The results suggest that plasma biomarkers can help detect preclinical Alzheimer's disease in asymptomatic individuals and improve diagnostic specificity, but the available summary does not report the size or strength of these effects.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants746
- Effect size64.3%; 20.6%; 22.7%
- Evidence strengthLow
How this study scored 60/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA network open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 746 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 37 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.4 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 6.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 34 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Richard P Mayeux: h-index 158 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Columbia University: institution h-index 1,824 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37079306) |
| Free to read | 2 / 2 | Free to read |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2023.8214
- PubMed: 37079306
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.